Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now later-stage tilt

Septic Shock: later-stage trial registry

9 of 25 indexed Septic Shock trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #652 of 28,707 conditions by registered trial count.

25 US clinical trials · 9 currently recruiting · #652 of 28,707 conditions by registered trial count

Septic Shock: 25 US clinical trials tracked, 9 recruiting.

Septic Shock is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Spectral Diagnostics (US), running 2 of these trials.

Enrollment posture brief

Registry condition septic-shock

OPEN 9 | RECR 36% | LATE 7 | EARLY 2 | RANK #652 | SPON 2

Nearest open-share peer: Cannabis (36% recruiting · 25 trials)

Alpha-1 Antitrypsin Deficien48%Alcohol Use40%Acute Lymphocytic Leukemia36%Alcohol-Related Disorders36%Septic Shock (this)36%
Open-enrollment share among volume-matched conditions near Septic Shock

Septic Shock lists 9 open slots (36% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Septic Shock on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Septic Shock is recruiting below its size-band peers.

    9 of 25 indexed trials (36%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Septic Shock trials is spread across many organizations.

    Spectral Diagnostics (US) accounts for 2 of 25 trials (8%). 23 distinct sponsors appear on at least one study for this condition label.

  3. Typical Septic Shock enrolment sits around 150 participants.

    Median target enrolment is 150 among the 25 trials that report a genuine target (sentinel values excluded). 11 of those (44%) plan for fewer than 100 participants.

  4. Septic Shock research is mostly interventional.

    19 interventional and 6 observational studies make up this index (76% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 32Phase 45

Open and recent trials

25 total, page 1 of 1

RECRUITING NA 52,500 participants

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

Children's Hospital of Philadelphia

NCT05975671

RECRUITING NA 10,000 participants

Assessment for Implementation Methods in Sepsis

Rhode Island Hospital

NCT05491941

RECRUITING Phase 3 500 participants

Stress Hydrocortisone In Pediatric Septic Shock

Jerry Zimmerman

NCT03401398

RECRUITING Phase 4 300 participants

Early Versus Late Adjunctive Vasopressin in Septic Shock

The Cleveland Clinic

NCT06709573

RECRUITING Phase 4 50 participants

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

Kingman Regional Medical Center

NCT06122987

RECRUITING Phase 3 46 participants

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

Vivacelle Bio

NCT06072430

RECRUITING NA 34 participants

Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

University of Oklahoma

NCT03992378

RECRUITING Phase 4 20 participants

Early Angiotensin II in the Emergency Department

Brett A Faine

NCT06693726

RECRUITING NA 10 participants

External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients

University of Pennsylvania

NCT04855786

ACTIVE NOT RECRUITING 50,000 participants

Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia

Henry Ford Health System

NCT05296590

ACTIVE NOT RECRUITING Phase 4 2,050 participants

Vasopressin for Septic Shock Pragmatic Trial

Intermountain Health Care

NCT06217562

ACTIVE NOT RECRUITING NA 150 participants

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

Spectral Diagnostics (US)

NCT03901807

ACTIVE NOT RECRUITING NA 15 participants

Blood Purification for the Treatment of Pathogen Associated Shock

ExThera Medical Corporation

NCT05011656

COMPLETED NA 2,296 participants

Predictive algoRithm for EValuation and Intervention in SEpsis

Dascena

NCT03235193

COMPLETED 1,055 participants

Evaluation of the Heparin Binding Protein Levels in Sepsis

Christiana Care Health Services

NCT02533011

COMPLETED 945 participants

Time to Lose the Weight? Comparison of Weight-based and Non-weight-based Vasopressors for Septic Shock

Methodist Health System

NCT04153578

COMPLETED NA 450 participants

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock

Spectral Diagnostics (US)

NCT01046669

COMPLETED 330 participants

Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock

University of British Columbia

NCT01867905

COMPLETED NA 300 participants

Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation

National Institute of General Medical Sciences (NIGMS)

NCT00372502

COMPLETED 150 participants

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

Abionic

NCT04409561

COMPLETED Phase 2 84 participants

HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients

University of Tennessee Medical Center

NCT03710187

COMPLETED NA 56 participants

Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock

National Center for Research Resources (NCRR)

NCT00005890

COMPLETED Phase 4 40 participants

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

University of New Mexi

NCT05824767

COMPLETED Phase 1 20 participants

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

George Washington University

NCT01393782

COMPLETED 18 participants

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

The Cleveland Clinic

NCT03014063

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 2
Phase 4 5

Named interventions

Most-linked intervention names on Septic Shock records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Angiotensin II Drug
2 trials
Blood collection Device
1 trials
Standard EGDT Procedure
1 trials
Modified EGDT Procedure
1 trials
Standard medical care for septic shock Other
1 trials
TORAYMYXIN PMX-20R (PMX cartridge) Device
1 trials
HBP lab test Other
1 trials
Severe Sepsis Detection Other
1 trials

US sites by state

Facility locations filed on Septic Shock trials. A trial with sites in several states counts in each.

Pennsylvania 5 trials
Ohio 5 trials
Georgia 5 trials
Arizona 5 trials
Michigan 4 trials
Massachusetts 4 trials
Texas 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Septic Shock page

25 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Septic Shock condition card totals 25 registered trials; most-linked intervention Angiotensin II; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.